Citations

Mayo Clinic

Showing 10 of 108551 citations.

Salvage Microsurgery Following Failed Primary Radiosurgery in Sporadic Vestibular Schwannoma
Marinelli, John P. , Herberg, Hans A., Moore, Lindsay S. , Kay‐Rivest, Emily , Casale, Garrett G. , Durham, Allison, Khandalavala, Karl R. , Lund‐Johansen, Morten , Kosaraju, Nikitha , Lohse, Christine M. , Patel, Neil S. , Babu, Seilesh C. , Golfinos, John G. , Kutz, Joe Walter , Maria, Peter L. Santa , Link, Michael J. , Tveiten, Øystein Vesterli , Carlson, Matthew L. , Yancey, Kristen L. , Gurgel, Richard Klaus , Roland, J. Thomas , Hunter, Jacob B.

JAMA Otolaryngology–Head & Neck Surgery | February 15, 2024 | Volume: 150 | Issue: 4 | Pages: 287

10.1001/jamaoto.2023.4474 | PMID 38358763 Get It

ImportanceManagement of sporadic vestibular schwannoma with radiosurgery is becoming increasingly common globally; however, limited data currently characterize patient outcomes in the setting of microsurgical salvage for radiosurgical failure.ObjectiveTo describe the clinical outcomes of salvage microsurgery following failed primary stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) among patients with sporadic vestibular schwannoma.Design, Setting, and ParticipantsThis was a cohort study of adults (≥18 years old) with sporadic vestibular schwannoma who underwent salvage microsurgery following failed primary SRS/FSRT in 7 vestibular schwannoma treatment centers across the US and Norway. Data collection was performed between July 2022 and January 2023, with data analysis performed between January and July 2023.ExposureSalvage microsurgical tumor resection.Main Outcomes and MeasuresComposite outcome of undergoing less than gross total resection (GTR) or experiencing long-term facial paresis.ResultsAmong 126 patients, the median (IQR) age at time of salvage microsurgery was 62 (53-70) years, 69 (55%) were female, and 113 of 117 (97%) had tumors that extended into the cerebellopontine angle at time of salvage. Of 125 patients, 96 (76%) underwent primary gamma knife SRS, while 24 (19%) underwent linear accelerator-based SRS; the remaining patients underwent FSRT using other modalities. Postoperative cerebrospinal fluid leak was seen in 15 of 126 patients (12%), hydrocephalus in 8 (6%), symptomatic stroke in 7 (6%), and meningitis in 2 (2%). Each 1-mm increase in cerebellopontine angle tumor size was associated with a 13% increased likelihood of foregoing GTR (64 of 102 patients [63%]) or long-term postoperative House-Brackmann grade higher than I (48 of 102 patients [47%]) (odds ratio, 1.13; 95% CI, 1.04-1.23). Following salvage microsurgery, tumor growth–free survival rates at 1, 3, and 5 years were 97% (95% CI, 94%-100%), 93% (95% CI, 87%-99%), and 91% (95% CI, 84%-98%), respectively.ConclusionsIn this cohort study, more than half of patients who received salvage microsurgery following primary SRS/FSRT underwent less than GTR or experienced some degree of facial paresis long term. These data suggest that the cumulative risk of developing facial paresis following primary SRS/FSRT by the end of the patient’s journey with treatment approximates 2.5% to 7.5% when using published primary SRS/FSRT long-term tumor control rates.
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma
Szlosarek, Peter W. , Creelan, Ben , Sarkodie, Thomas, Nolan, Luke, Olevsky, Olga, Grosso, Federica , Roy, Amy, Gilligan, David , Kindler, Hedy L. , Papadatos-Pastos, Dionysis, O’Byrne, Kenneth J. , Nowak, Anna K. , Steele, Jeremy, Sheaff, Michael , Shiu, Chiung‐Fang, Kuo, Chih‐Ling, Johnston, Amanda , Group, ATOMIC-Meso Study, Mackean, Melanie , Steele, Nicola , Upadhyay, Sunil , Srivastav, Ratnesh Kumar , Mencoboni, Manlio, Zilembo, Nicoletta, Marinis, Filippo de , Stella, Maria Giulia, Wang, Chin‐Chou , Nowak, Anna K , Taylor, Paul D. , Cortinovis, Diego Luigi , Chitnis, Meenali M. , Ceresoli, Giovanni Luca , Mansfield, Aaron S. , Tsao, Anne S. , Bomalaski, John S. , Zauderer, Marjorie G. , Fennell, Dean Anthony , Group, ATOMIC-Meso Study, Rybkin, Igor I. , Rolfo, Christian , Franks, K. , Shaw, Paul Nicholas , Lind, Michael , John, Thomas , Karapetis, Christos Stelios , Chella, Antonio , Stella, Maria Giulia, Chong, Inn‐Wen

JAMA Oncology | February 15, 2024 | Volume: 10 | Issue: 4 | Pages: 475

10.1001/jamaoncol.2023.6789 | PMID 38358753 Get It

ImportanceArginine deprivation using ADI-PEG20 (pegargiminase) combined with chemotherapy is untested in a randomized study among patients with cancer. ATOMIC-Meso (ADI-PEG20 Targeting of Malignancies Induces Cytotoxicity-Mesothelioma) is a pivotal trial comparing standard first-line chemotherapy plus pegargiminase or placebo in patients with nonepithelioid pleural mesothelioma.ObjectiveTo determine the effect of pegargiminase-based chemotherapy on survival in nonepithelioid pleural mesothelioma, an arginine-auxotrophic tumor.Design, Setting, and ParticipantsThis was a phase 2-3, double-blind randomized clinical trial conducted at 43 centers in 5 countries that included patients with chemotherapy-naive nonepithelioid pleural mesothelioma from August 1, 2017, to August 15, 2021, with at least 12 months’ follow-up. Final follow-up was on August 15, 2022. Data analysis was performed from March 2018 to June 2023.InterventionPatients were randomly assigned (1:1) to receive weekly intramuscular pegargiminase (36.8 mg/m2) or placebo. All patients received intravenous pemetrexed (500 mg/m2) and platinum (75-mg/m2 cisplatin or carboplatin area under the curve 5) chemotherapy every 3 weeks up to 6 cycles. Pegargiminase or placebo was continued until progression, toxicity, or 24 months.Main Outcomes and MeasuresThe primary end point was overall survival, and secondary end points were progression-free survival and safety. Response rate by blinded independent central review was assessed in the phase 2 portion only.ResultsAmong 249 randomized patients (mean [SD] age, 69.5 [7.9] years; 43 female individuals [17.3%] and 206 male individuals [82.7%]), all were included in the analysis. The median overall survival was 9.3 months (95% CI, 7.9-11.8 months) with pegargiminase-chemotherapy as compared with 7.7 months (95% CI, 6.1-9.5 months) with placebo-chemotherapy (hazard ratio [HR] for death, 0.71; 95% CI, 0.55-0.93; P = .02). The median progression-free survival was 6.2 months (95% CI, 5.8-7.4 months) with pegargiminase-chemotherapy as compared with 5.6 months (95% CI, 4.1-5.9 months) with placebo-chemotherapy (HR, 0.65; 95% CI, 0.46-0.90; P = .02). Grade 3 to 4 adverse events with pegargiminase occurred in 36 patients (28.8%) and with placebo in 21 patients (16.9%); drug hypersensitivity and skin reactions occurred in the experimental arm in 3 patients (2.4%) and 2 patients (1.6%), respectively, and none in the placebo arm. Rates of poststudy treatments were comparable in both arms (57 patients [45.6%] with pegargiminase vs 58 patients [46.8%] with placebo).Conclusions and RelevanceIn this randomized clinical trial of arginine depletion with pegargiminase plus chemotherapy, survival was extended beyond standard chemotherapy with a favorable safety profile in patients with nonepithelioid pleural mesothelioma. Pegargiminase-based chemotherapy as a novel antimetabolite strategy for mesothelioma validates wider clinical testing in oncology.Trial RegistrationClinicalTrials.gov Identifier: NCT02709512
Therapeutic restoration of miR-126-3p as a multi-targeted strategy to modulate the liver tumor microenvironment
Gondaliya, Piyush , Driscoll, Julia , Yan, Irene K. , Sayyed, Adil Ali , Ali Sayyed, Adil , Patel, Tushar , Ali Sayyed, Adil , Patel, Tushar

Hepatology Communications | February 15, 2024 | Volume: 8 | Issue: 3 | Pages: No page available

10.1097/hc9.0000000000000373 | PMID 38358374 Get It

Background: Impaired natural killer (NK) cell-mediated antitumor responses contribute to the growth of liver tumors. Expression of a disintegrin and metalloprotease 9 (ADAM9) increases shedding of membrane-bound major histocompatibility complex class I chain-related protein A and results in evasion from NK cell-mediated cytolysis. ADAM9 is also involved in angiogenesis and tumor progression and is a target of miR-126-3p, a tumor suppressor that is downregulated and alters tumor cell behavior in the liver and other cancers. We evaluated the restoration of miR-126-3p and modulation of the miR-126-3p/ADAM9 axis as a therapeutic approach to simultaneously enhance NK cell-mediated cytolysis while targeting both tumor cells and their microenvironment. Methods: Precursor miRNAs were loaded into milk-derived nanovesicles to generate therapeutic vesicles (therapeutic milk-derived nanovesicles) for the restoration of functional miR-126-3p in recipient cancer cells. Results: Administration of therapeutic milk-derived nanovesicles increased miR-126-3p expression and reduced ADAM9 expression in target cells and was associated with an increase in membrane-bound major histocompatibility complex class I chain-related protein A. This enhanced NK cell cytolysis in adherent tumor cells and in multicellular tumor spheroids while also impairing angiogenesis and modulating macrophage chemotaxis. Moreover, IV administration of therapeutic milk-derived nanovesicles with adoptive transfer of NK cells reduced tumor burden in orthotopic hepatocellular cancer xenografts in mice. Conclusion: A directed RNA therapeutic approach can mitigate NK cell immune evasion, reduce angiogenesis, and alter the tumor cell phenotype through the restoration of miR-126-3p in liver tumor cells. The pleiotropic effects elicited by this multi-targeted approach to modulate the local tumor microenvironment support its use for the treatment of liver cancer.
Gender Disparities in Academic Otolaryngology
Ladlie, Beth L., Case, Hannah F., Perisetla, Priyanka, Austin, Andrew, Craver, Emily C. , Engelberg‐Cook, Erica, Rutt, Amy L. , Engelberg-Cook, Erica , Rutt, Amy L. , Case, Hannah

The Laryngoscope | February 15, 2024 | Volume: 134 | Issue: 5 | Pages: 2144-2152

10.1002/lary.31217 | PMID 38358356 Get It

ObjectiveThe aim was to evaluate representation of women in otolaryngology by examining authorship of research publications and presentations, awards, research grants, leadership, and membership in related organizations.MethodsAuthorship was reviewed from articles published in three otolaryngology journals from 2000 through 2021 to assess the frequency and percentages of female and combination of male and female gender authorship. Gender was evaluated for poster and scientific abstract presentations from 2007 to 2021. Gender representation was reviewed for institutional and society leadership positions, award, and grant recipients in the American Laryngological Society (ALA). Changes in the frequency of female and combination of male and female gender authorship over time were examined with Cochran‐Armitage test for trend.ResultsA total of 16,921 articles, 1,017 presentations, 480 leadership positions, 129 president positions, and 1,137 awards and grants were studied. Women were first authors in 4,153 (24.9%) and last authors in 2,935 (17.8%) published articles for which gender could be determined. Women were first authors in 372 (37.4%) presentations and last authors in 199 (20.2%). Most presentations had a combination of male and female presentation authorship (630, 68%). Women held 69 (14.4%) leadership positions. Of the award and grant recipients, 327 (28.8%) were female. Significant trends were observed for increasing female representation (first authorship publications increased 69.9% from 2000 to 2020, first authorship presentations increased 73.9% from 2007 to 2013, p < 0.001; leadership and awards from 3% to 18% representation, p = 0.02).ConclusionThe proportion of women receiving awards and holding leadership positions is increasing. Efforts that promote gender diversity may further increase representation of women in otolaryngology literature and among the grant and award winners.Level of EvidenceNA Laryngoscope, 134:2144–2152, 2024
Evaluation of Intracardiac Pressures Using Subharmonic-aided Pressure Estimation with Sonazoid Microbubbles
Esposito, Cara , Machado, Priscilla , McDonald, Maureen E. , Savage, Michael P. , Fischman, David L. , Mehrotra, Praveen , Cohen, Ira S. , Ruggiero, Nicholas , Walinsky, Paul, Vishnevsky, Alec, Dickie, Kristopher, Davis, Marguerite , Forsberg, Flemming , Dave, Jaydev K. , Fischman, David

Radiology: Cardiothoracic Imaging | February 15, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1148/ryct.230153 | PMID 38358329 Get It

Levothyroxine Sodium Soft Gelatin Capsules in Thyroidectomized Patients Taking Proton–Pump Inhibitors: Are They More Effective than Tablets?
Kawkgi, Omar El

Clinical Thyroidology® | February 15, 2024 | Volume: 36 | Issue: 2 | Pages: 51-54

10.1089/ct.2024;36.51-54 Get It

Biliary Disorders, Anomalies, and Malignancies in Children
Simmons, Curtis , Harper, Laura K , Patel, Mittun C. , Katabathina, Venkat S. , Southard, Richard , Gonçalves, Luís F. , Tran, Evelyn , Biyyam, Deepa R. , Simmons, Curtis L , Southard, Richard N , Goncalves, Luis

RadioGraphics | February 15, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1148/rg.230109 | PMID 38358937 Get It

Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework
Peipert, John Devin , Basch, Ethan , Cella, David , Smith, Mary Lou , Thanarajasingam, Gita , Peipert, John Devin , Breslin, Monique C. , Basch, Ethan , Calvert, Melanie , Roydhouse, Jessica

Journal of Biopharmaceutical Statistics | February 15, 2024 | Volume: 35 | Issue: 5 | Pages: 793-811

10.1080/10543406.2024.2313060 | PMID 38358291 Get It

Unraveling the Genetic Landscape of Neurological Disorders: Insights into Pathogenesis, Techniques for Variant Identification, and Therapeutic Approaches
Firdaus, Zeba , Li, Xiaogang

International Journal of Molecular Sciences | February 15, 2024 | Volume: 25 | Issue: 4 | Pages: 2320

10.3390/ijms25042320 | PMID 38396996 Get It

Genetic abnormalities play a crucial role in the development of neurodegenerative disorders (NDDs). Genetic exploration has indeed contributed to unraveling the molecular complexities responsible for the etiology and progression of various NDDs. The intricate nature of rare and common variants in NDDs contributes to a limited understanding of the genetic risk factors associated with them. Advancements in next-generation sequencing have made whole-genome sequencing and whole-exome sequencing possible, allowing the identification of rare variants with substantial effects, and improving the understanding of both Mendelian and complex neurological conditions. The resurgence of gene therapy holds the promise of targeting the etiology of diseases and ensuring a sustained correction. This approach is particularly enticing for neurodegenerative diseases, where traditional pharmacological methods have fallen short. In the context of our exploration of the genetic epidemiology of the three most prevalent NDDs—amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease, our primary goal is to underscore the progress made in the development of next-generation sequencing. This progress aims to enhance our understanding of the disease mechanisms and explore gene-based therapies for NDDs. Throughout this review, we focus on genetic variations, methodologies for their identification, the associated pathophysiology, and the promising potential of gene therapy. Ultimately, our objective is to provide a comprehensive and forward-looking perspective on the emerging research arena of NDDs.
Transforming Outcomes of Spine Surgery—Exploring the Power of Enhanced Recovery After Surgery Protocol: A Systematic Review and Meta-Analyses of 15 198 Patients
Magableh, Hamzah M , Ibrahim, Sufyan , Pennington, Zach , Nathani, Karim Rizwan , Johnson, Sarah E. , Freedman, Brett A. , Bydon, Mohamad , Pennington, Zachary, Katsos, Konstantinos, Pennington, Zach , Nathani, Karim Rizwan , Ibrahim, Sufyan , Katsos, Konstantinos

Neurosurgery | February 15, 2024 | Volume: 95 | Issue: 1 | Pages: 3-25

10.1227/neu.0000000000002865 | PMID 38358272 Get It

BACKGROUND AND OBJECTIVES: Enhanced recovery after surgery (ERAS) protocols aim to optimize patient outcomes by reducing the surgical stress response, expediting recovery, and reducing care costs. We aimed to evaluate the impact of implementing ERAS protocols on the perioperative surgical outcomes and financial implications associated with spine surgeries. METHODS: A systematic review and meta-analysis of peer-reviewed studies directly comparing outcome differences between spine surgeries performed with and without utilization of ERAS pathways was conducted along Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: Of 676 unique articles identified, 59 with 15 198 aggregate patients (7748 ERAS; 7450 non-ERAS) were included. ERAS-treated patients had shorter operative times (mean difference [MD]: 10.2 mins; P < .01), shorter hospitalizations (MD: 1.41 days, P < .01), fewer perioperative complications (relative risk [RR] = 0.64, P < .01), lower postoperative opioid use (MD of morphine equivalent dose: 164.36 mg; P < .01), and more rapid mobilization/time to first out-of-bed ambulation (MD: 0.92 days; P < .01). Spine surgeries employing ERAS were also associated with lower total costs (MD: $1140.26/patient; P < .01), especially in the United States (MD: $2869.11/patient, P < .01) and lower postoperative visual analog pain scores (MD = 0.56, P < .01), without any change in odds of 30-day readmission (RR: 0.80, P = .13) or reoperation (RR: 0.88, P = .60). Subanalyses based on the region of spine showed significantly lower length of stay in both cervical and lumbar surgeries implementing ERAS. Type of procedure showed a significantly lesser time-to-initiate mobilization in fusion surgeries using ERAS protocols compared with decompression. CONCLUSION: The present meta-analysis indicates that current literature supports ERAS implementation as a means of reducing care costs and safely accelerating hospital discharge for patients undergoing spine surgery.